Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

Yumita, Sae; Ogasawara, Sadahisa; Nakagawa, Miyuki; Maruta, Susumu; Okubo, Tomomi; Itokawa, Norio; Iino, Yotaro; Obu, Masamichi; Haga, Yuki; Seki, Atsuyoshi; Kogure, Tadayoshi; Ishino, Takamasa; Ogawa, Keita; Fujiwara, Kisako; Iwanaga, Terunao; Fujita, Naoto; Sakuma, Takafumi; Kojima, Ryuta; Kanzaki, Hiroaki; Koroki, Keisuke; Inoue, Masanori; Kobayashi, Kazufumi; Kiyono, Soichiro; Nakamura, Masato; Kanogawa, Naoya; Saito, Tomoko; Kondo, Takayuki; Nakagawa, Ryo; Nakamoto, Shingo; Muroyama, Ryosuke; Chiba, Tetsuhiro; Itobayashi, Ei; Atsukawa, Masanori; Koma, Yoshihiro; Azemoto, Ryosaku; Ito, Kenji; Mizumoto, Hideaki; Kato, Jun; Kato, Naoya

doi:10.1186/s12876-023-02731-5

BMC Gastroenterology

Article metrics
Last updated: Thu, 2 May 2024 12:37:58 Z

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

Access & Citations

1891

Article Accesses
0

Web of Science
0

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-230X

Contact us

Submission enquiries: bmcgastroenterology@biomedcentral.com
General enquiries: ORSupport@springernature.com